Indications: Tagrix 40 mg is prescribed for patients diagnosed with metastatic non-small cell lung cancer (NSCLC) harboring the T790M mutation in the epidermal growth factor receptor (EGFR), as identified by an FDA-approved test. This medication is intended for those whose disease has progressed despite prior treatment with EGFR tyrosine kinase inhibitor (TKI) therapy.

Pharmacology: Tagrix 40 mg acts as an EGFR tyrosine kinase inhibitor (TKI), targeting specific mutant forms of EGFR (including T790M, L858R, and exon 19 deletion) commonly found in NSCLC tumors post-initial EGFR-TKI treatment. As a third-generation TKI, Tagrix 40 mg selectively binds to the gate-keeper T790M mutation, thereby increasing ATP binding activity to EGFR and influencing the prognosis of late-stage disease. Notably, Tagrix 40 mg is designed to spare wild-type EGFR during treatment, thereby minimizing non-specific binding and associated toxicity.

Dosage and Administration: The recommended dosage of Tagrix 40 mg is 80 mg once daily, to be taken until disease progression or unacceptable adverse effects occur. Tagrix 40 mg can be administered with or without food. In case of a missed dose, patients should not double up on the next dose; instead, they should resume the regular dosing schedule.

Interaction: Tagrix 40 mg may interact with strong CYP3A4 inducers. If coadministration with a strong CYP3A4 inducer is unavoidable, the dosage of Tagrix 40 mg should be increased to 160 mg daily. After discontinuation of the strong CYP3A4 inducer, Tagrix 40 mg should be resumed at the standard 80 mg dose after a three-week interval.

Side Effects: Common side effects associated with Tagrix 40 mg include interstitial lung disease or pneumonitis, QTc interval prolongation, cardiomyopathy, and keratitis.

Precautions and Warnings: Prior to initiating treatment with Tagrix 40 mg, healthcare providers should consider the following precautions and warnings:

Overdose Effects: Information regarding overdose effects of Tagrix 40 mg is limited. In the event of suspected overdose, appropriate supportive measures should be initiated. Patients should seek immediate medical attention if an overdose is suspected.Patients should adhere to the prescribed regimen and consult their healthcare provider for personalized recommendations and guidance on the use of Tagrix 40 mg for NSCLC treatment.